A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis
…, J Van Ingen, C Magis-Escurra… - American journal of …, 2015 - atsjournals.org
Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic,
toxicity, and cost considerations. Available data in mice and humans showed that an …
toxicity, and cost considerations. Available data in mice and humans showed that an …
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
…, Y Li, C Magis-Escurra… - European …, 2019 - Eur Respiratory Soc
The World Health Organization (WHO) recommends that countries implement pharmacovigilance
and collect information on active drug safety monitoring (aDSM) and management of …
and collect information on active drug safety monitoring (aDSM) and management of …
[HTML][HTML] Multidrug-resistant tuberculosis in Europe, 2010–2011
…, V Leimane, C Magis-Escurra… - Emerging infectious …, 2015 - ncbi.nlm.nih.gov
MDR TB living in this region may be much higher because a substantial proportion of patients
are never screened for drug-resistant TB before starting treatment, partly because of a lack …
are never screened for drug-resistant TB before starting treatment, partly because of a lack …
[HTML][HTML] The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis
…, H Orozco, D Aguilar, C Magis-Escurra… - PloS one, 2010 - journals.plos.org
Multidrug- and extensively drug-resistant tuberculosis have emerged as grave threats to public
health worldwide. Very few active drugs are available or likely to become available soon. …
health worldwide. Very few active drugs are available or likely to become available soon. …
[HTML][HTML] Epidemiology of Mycobacterium bovis disease in humans, The Netherlands, 1993–2007
CJ Majoor, C Magis-Escurra, J van Ingen… - Emerging infectious …, 2011 - ncbi.nlm.nih.gov
In the Netherlands, 1.4% of tuberculosis (TB) cases are caused by Mycobacterium bovis.
After we admitted 3 patients with M. bovis infections to our reference hospital, we conducted a …
After we admitted 3 patients with M. bovis infections to our reference hospital, we conducted a …
Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients
…, CW Jacobs, C Magis‐Escurra… - Clinical & …, 2015 - Wiley Online Library
Background Allergic bronchopulmonary aspergillosis ( ABPA ) is characterised by an exaggerated
Th2 response to A spergillus fumigatus, but the immunological pathways responsible …
Th2 response to A spergillus fumigatus, but the immunological pathways responsible …
[HTML][HTML] Treatment outcomes in multidrug-resistant tuberculosis
…, V Leimane, C Magis-Escurra… - … England Journal of …, 2016 - Mass Medical Soc
Treatment Outcomes in Multidrug-Resistant Tuberculosis | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria
…, S Kuipers, C Magis-Escurra… - Journal of …, 2019 - academic.oup.com
Background Non-tuberculous mycobacteria (NTM) infections are hard to treat. New
antimicrobial drugs and smarter combination regimens are needed. Objectives Our aim was to …
antimicrobial drugs and smarter combination regimens are needed. Objectives Our aim was to …
[HTML][HTML] High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
…, R Aarnoutse, M Boeree, C Magis-Escurra - PLoS …, 2019 - journals.plos.org
Background Recent evidence suggests that higher rifampicin doses may improve tuberculosis
(TB) treatment outcome. Methods In this observational cohort study we evaluated all TB …
(TB) treatment outcome. Methods In this observational cohort study we evaluated all TB …
The potential of a portable, point-of-care electronic nose to diagnose tuberculosis
…, W Wiegerinck, DP Bejerano, C Magis-Escurra - Journal of Infection, 2017 - Elsevier
Introduction Tuberculosis (TB) is the leading cause of death due to an infectious disease
worldwide. Especially in low-income countries, new diagnostic techniques that are accessible, …
worldwide. Especially in low-income countries, new diagnostic techniques that are accessible, …